PSNL Personalis
- 3.690
- +0.100+2.79%
- 3.690
- 0.0000.00%
Personalis News
Morgan Stanley Maintains Personalis(PSNL.US) With Hold Rating, Maintains Target Price $5
Morgan Stanley Maintains Personalis(PSNL.US) With Hold Rating, Raises Target Price to $5
Personalis: Promising Growth in Biopharma Sales Amidst Strategic Challenges – Hold Rating Maintained
Here's Why We're Not Too Worried About Personalis' (NASDAQ:PSNL) Cash Burn Situation
Personalis Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
A Quick Look at Today's Ratings for Personalis(PSNL.US), With a Forecast Between $7 to $9
Personalis Inc (PSNL) Q3 2024 Earnings Call Highlights: Robust Revenue Growth Amid Strategic ...
Have Insiders Sold Personalis Shares Recently?
12 Health Care Stocks Moving In Thursday's Pre-Market Session
What Analysts Are Saying About Personalis Stock
H.C. Wainwright Maintains Personalis(PSNL.US) With Buy Rating, Maintains Target Price $9
Needham Maintains Personalis(PSNL.US) With Buy Rating, Maintains Target Price $7.25
Needham Reiterates Buy on Personalis, Maintains $7.25 Price Target
Personalis Analyst Ratings
Personalis: Strong Revenue Growth and Strategic Advances Justify Buy Rating
TD Cowen Maintains Personalis(PSNL.US) With Buy Rating
TD Cowen Remains a Buy on Personalis (PSNL)
Personalis Reports Solid Q3 Growth and Raises Revenue Outlook
Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript Summary
Personalis Shares Are Trading Lower After the Company Announced Worse-than-expected Q3 Financial Results.
Analysis
Price Target
No Data
No Data